|1.||Arakawa, Tetsuo: 10 articles (09/2015 - 07/2002)|
|2.||Yoshikawa, Toshikazu: 9 articles (12/2012 - 10/2005)|
|3.||Tominaga, Kazunari: 8 articles (09/2015 - 07/2002)|
|4.||Watanabe, Toshio: 7 articles (09/2015 - 07/2002)|
|5.||Fujiwara, Yasuhiro: 7 articles (09/2015 - 07/2002)|
|6.||Naito, Yuji: 6 articles (07/2015 - 10/2005)|
|7.||Higuchi, Kazuhide: 6 articles (07/2015 - 07/2002)|
|8.||Kinoshita, Shigeru: 5 articles (03/2014 - 12/2012)|
|9.||Ichikawa, Hiroshi: 5 articles (12/2012 - 10/2005)|
|10.||Sakamoto, Choitsu: 5 articles (01/2011 - 08/2005)|
11/01/1995 - "These results suggest that rebamipide is beneficial for obtaining a better quality of ulcer healing and reduction of future ulcer relapse."
01/01/2014 - "The results of this meta-analysis suggest that treatment with PPIs plus rebamipide is superior to PPI monotherapy for healing ESD-induced ulcers over four weeks, particularly large ulcers. "
01/01/2014 - "The subgroup analysis showed PPI plus rebamipide therapy to be more effective in healing ESD-induced ulcers than treatment with PPIs alone after both four (OR=2.22, 95%CI: 1.53-3.24) and eight weeks of treatment (OR=3.19, 95%CI: 1.22-8.31). "
03/01/2010 - "We examined the efficacy of a combination therapy of PPI and rebamipide, a mucosal-protective antiulcer drug, on the acceleration of post-ESD ulcer healing. "
09/14/2013 - "Efficacy of treatment with rebamipide for endoscopic submucosal dissection-induced ulcers."
10/01/2005 - "Nine of 11 (81.8%) patients on 12-week treatment with rebamipide approved and were classified as colitis in remission. "
09/07/2011 - "To investigate the efficacy of rebamipide in a rat model of colitis and restitution of intestinal epithelial cells in vitro. "
01/01/2007 - "Our aim was to study the effect of a mucosal protective agent, rebamipide, on the colonic barrier and the immune response in colitis-prone interleukin-10-deficient (IL-10-/-) C57BL/6 mice infected with Helicobacter hepaticus. "
01/01/2007 - "These results indicate that in IL-10-/- mice with mild colitis, rectally administered rebamipide reinforces the distal colonic barrier and has a slight Th1 immuno-stimulatory effect on mesenteric lymph node cells. "
08/01/2000 - "Rebamipide thus inhibited the induction of colitis. "
01/01/2014 - "This study aimed at developing a novel rebamipide liquid for an effective treatment of oral mucositis. "
11/01/2014 - "These results suggest that rebamipide is effective for the treatment of oral mucositis. "
11/01/2014 - "We hope to verify the preventive and protective effects of rebamipide by conducting a prospective, randomized trial while treating oral mucositis with basic oral care and appropriate interventions provided by a multidisciplinary team."
11/01/2014 - "Daily rebamipide was administered to patients with oral mucositis as per hospital protocol to evaluate the hypothesized preventive and mucosal protective effects of rebamipide(Mucosta®). "
01/01/2015 - "Because of its pharmacological properties including anti-inflammatory activity and stimulatory effects on endogenous prostaglandin synthesis, rebamipide has been suggested as a potentially effective treatment against stomatitis. "
|4.||Stomach Ulcer (Gastric Ulcer)
07/01/2000 - "Rebamipide is a new mucosal protective drug, which is effective in healing gastric ulcers. "
02/01/2008 - "Rebamipide, anti-gastric ulcer drug, has protective effects in a variety of tissue and organ injury. "
08/01/2007 - "We examined the efficacy of rebamipide in gastric ulcer healing following 1 week of eradication therapy in a randomized, double-blind, placebo-controlled trial. "
09/01/2014 - "Some randomized controlled trials showed that a combination of rebamipide and PPI appears to be more efficient than PPI alone for the treatment of ESD-induced gastric ulcer. "
01/01/2011 - "A recent placebo-controlled trial showed that rebamipide, which is a mucosal-protective antiulcer agent, promoted gastric ulcer healing without affecting the Helicobacter pylori status. "
10/01/2015 - "Rebamipide improved the clinical symptoms, gastric mucosal lesions, and pathological grades of chronic gastritis patients and decreased the expression rates of CDX2 and TFF3 in gastric cells."
11/01/2008 - "In conclusion, rebamipide treatment improved symptom, endoscopic, and histologic features of chronic gastritis in patients with refractory dyspeptic symptoms."
10/01/2015 - "Effect of Rebamipide on the Premalignant Progression of Chronic Gastritis: A Randomized Controlled Study."
10/01/2015 - "Rebamipide is a free radical scavenger and we assessed its efficacy on clinical symptoms, gastric mucosal lesions, pathologic grade, and immunohistochemistry in chronic gastritis patients. "
06/01/2015 - "Rebamipide is a routine drug for the treatment of gastritis in a clinical setting. "
|3.||Proton Pump Inhibitors
|4.||Diclofenac (SR 38)
|5.||Proton Pumps (Proton Pump)
|6.||Acetic Acid (Vinegar)
|7.||Aspirin (Acetylsalicylic Acid)
|2.||Drug Therapy (Chemotherapy)